Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220889 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants
A Phase 1 study of Safety After Oral Intake, sponsored by MDI Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT07220889 is a Phase 1 study of Safety After Oral Intake that is actively recruiting participants, run by MDI Therapeutics. The registered enrollment target is 52 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07220889, a Phase 1 study of Safety After Oral Intake, is actively recruiting participants, sponsored by MDI Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if drug MDI2517 is safe and to learn more about its drug effects in healthy participants. Healthy participants will take single or multiple doses of drug and the safety and drug levels will be measured.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MDI-2517 800mg
- DRUG MDI-2517 1600mg
- DRUG MDI-2517 2400mg
- DRUG MDI-2517 3600mg
Study Locations (1)
Florida
- 1951 NW 7th Avenue, Suite 180 - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2026-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220889
The ClinicalTrials.gov registry entry for NCT07220889 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MDI Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Safety After Oral Intake appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT07220889 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07220889 about?
NCT07220889 is a clinical study titled "Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants". The goal of this clinical trial is to learn if drug MDI2517 is safe and to learn more about its drug effects in healthy participants. Healthy participants will take single or multiple doses of drug and the safety and drug levels will be measured.
What is the current status of trial NCT07220889?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2025-11-04. Estimated completion is 2026-06-04.
What conditions does trial NCT07220889 study?
This clinical trial studies the following conditions: Safety After Oral Intake.
What interventions are being tested in trial NCT07220889?
The interventions under investigation include: Placebo (OTHER), MDI-2517 800mg (DRUG), MDI-2517 1600mg (DRUG), MDI-2517 2400mg (DRUG), MDI-2517 3600mg (DRUG).
Who is sponsoring clinical trial NCT07220889?
This trial is sponsored by MDI Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220889 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Safety After Oral Intake
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.